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Available online 30 July 2016AbstractThe greatest burden of hip fractures around the world is expected to occur in East Asia, especially China. However, there is a relative paucity
of information on the epidemiology and burden of fractures in East Asia. Osteoporosis is greatly under-diagnosed and under-treated, even among
the highest-risk subjects who have already suffered fractures. The accessibility to bone densitometry, the awareness of the disease by pro-
fessionals and the public, and the use and reimbursement of drugs are some of the areas which need improvement especially. Cost-effective
analysis on screening strategy and intervention thresholds based on local epidemiology data and economic status are available only in Japan.
In addition, clinical risk factor models for the assessment of fracture probability may be ethnic specific. Further research is needed to develop a
cost-effective risk assessment strategy to identify high-risk individuals for screening and treatment based on local data. Moreover, inadequate
calcium and vitamin D intake is still an issue faced by this region.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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As classified by the United Nations, East Asia contains
Hong Kong, Japan, Macau, Mongolia, North Korea, the Peo-
ple's Republic of China, South Korea and Taiwan. In this re-
gion, osteoporosis is increasingly being recognised as a
growing problem [1,2] because of the rapidly increasing size
of the elderly population. In particular, China has the largest
aged population in the world, as the population aged 60
years will reach 400 million (approximately 30% of the total
population) by 2050 [3]. In Japan, the percentage of the
population aged 65 years rose from 10.3% in 1985 to 20.1%
in 2005 [4]; this percentage is expected to double by 2050 [4].
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).in 1980 to 10.74% in 2010 [5]. As in the West, there is an
exponential increase in the incidence of hip fractures after the
age of 65 in Asian populations [6]. For example, the hip
fracture incidence has more than doubled for each successive
5-year age group in Hong Kong [7].
In this review, we highlighted the differences and similar-
ities in the assessment and treatment between the East and
West. We focused mainly on hip and vertebral fractures
because they account for the majority of fracture-related
mortality and morbidity as well as health care expenditure.
We identified data for this review by a systematic search of
Medline with the MeSH terms “Osteoporosis” and “East Asia”
for peer-reviewed clinical studies and other studies of clinical
significance. This search was not restricted to reports written
in English; articles written in a native language but that
included an English abstract were included as well. The re-
view included articles published between June 1996 and
November 2015. Bibliographies of identified articles, guide-
lines and conference proceedings of professional societieslsevier B.V. This is an open access article under the CC BY-NC-ND license
Table 1
Annual age specific hip fracture incidence in East Asia.
Place Sampling
method
Years of
study
Incidence
per 10,000
Ref
China Beijing hospital
discharge record
2002e2006 12.9 50M [15]
22.9 50F
HK Region-wide
public hospitals
database
2000e2004 21.22 70e74M [7]
36.44 70e74F
45 75e79M
83.08 75e79F
87.14 80e84M
150.38 80e84F
165.44 85M
283.76 85F
Japan Nation-wide
estimate
2007 18.12 70e79M [12]
39.71 70e79F
61.03 80e89M
157.14 80e89F
146.62 90 þ M
313.58 90 þ F
South
Korea
Nation-wide 2005e2008 2.38 50e59M [13]
1.81 50e59F
60.58 80e100M
105.25 80e100F
Taiwan Nation-wide 2002 36.23 70e74M [14]
51.13 70e74F
59.2 75e79M
99.1 75e79F
93.83 80e84M
178.37 80e84F
153.03 85M
274.55 85F
119E.Y.N. Cheung et al. / Osteoporosis and Sarcopenia 2 (2016) 118e133were reviewed for additional references. Review articles and
book chapters were cited to provide readers with additional
details and references. In this discussion, we gave more weight
to randomised controlled trials and meta-analyses than evi-
dence of lower quality. Data presented here are from China,
Hong Kong, Japan, South Korea and Taiwan. When selecting a
study or studies over others to represent the epidemiology of a
region or country, we chose national rather than regional data,
if available. We used the most recent studies and also studies
which examine greater number of subjects.
2. Epidemiology
While the burden of hip fractures is increasing markedly
throughout the world, the greatest impact is expected to be felt
in Asia; specifically, the percentage of hip fractures in Asia is
expected to rise from 26% in 1990 to 37% in 2025 [8]. By the
year 2050, half of all hip fractures in the world are projected to
occur in Asia, particularly in China [9].
In a recent systematic review of hip fractures incidence
worldwide, the age-standardised annual incidence of hip
fractures was reported to be higher in Hong Kong, Japan,
South Korea, and Taiwan than in the USA and some European
countries [10]. This is in contrast to a study 2 decades ago
which showed the hip fractures incidence to be higher in USA
compared to Hong Kong [11]. The recent decline and increase
in hip fracture incidence in USA and East Asia, respectively,
may partly account for this [2]. For women, Taiwan was in the
high-incidence category (incidence >300/100,000), ranking
number 9 among all 61 countries/regions. Hong Kong, Japan
and South Korea were in the medium-incidence category
(200e300/100,000), ranking 23, 32 and 34, respectively.
China was in the low-incidence category (<200/100,000). For
men, Japan, Korea and Taiwan were among the high-incidence
countries (>150/100,000), while China and Hong Kong were
in the moderate-incidence category (100e150/100,000). The
data used to compute hip fracture incidence in China, Hong
Kong, Japan, South Korea and Taiwan in this study were from
publications in the years 2011, 2009, 2006, 2008 and 2009,
respectively. Updated incidence rates of hip fractures were
reported from Japan and South Korea in 2009 [12] and 2011
[13], respectively. These specific hip fractures incidence rates
are summarised in Table 1 [7,12e15].
Following the trend in to the West [2], the age-specific
incidence of hip fractures seems to have been stabilising in
the past decade, especially in the age group <80 years in Hong
Kong [16], Japan [12] and South Korea [13]. The increase in
BMD, healthier lifestyles (more exercise and higher vitamin D
levels) and longer reproductive periods may be responsible for
this [17]. Nonetheless, the overall number of hip fractures is
still increasing in China [15], Japan [12,18] and South Korea
[13]. It is attributable largely to the ageing populations, but
may partly due also to improved reporting [19]. In Japan, the
estimated number of hip fractures for both sexes per year for
all age groups increased 2.78-fold from 53,200 in 1987 to
148,100 in 2007 [12]. In South Korea, from 2005 to 2008, the
total number of hip fractures for subjects aged 50 yearsnation-wide increased by 21% (from 16,866 in 2005 to 20,432
in 2008) [13].
Comparison of the prevalence of vertebral fractures be-
tween populations is difficult due to the lack of a gold standard
for the definition of vertebral fracture and also because of the
different age groups included in these studies (Table 2).
Similar to the situation in the West [20], about three-fourths of
vertebral fractures in East Asia [21e24] were not diagnosed
clinically. The updated age-specific prevalence of vertebral
fractures among female populations in various East Asia
countries and White Caucasian women using different
methods is summarised in Table 2 [25e34]. The age-specific
data on men is sparser [28,35,36]. The prevalence of hip
fractures in men was considered to be higher in Japan [37],
followed by Hong Kong and Taiwan [28]. Prior vertebral
fracture was an important risk factor for future vertebral
fractures [28,37,38] and hip fractures [38,39].
3. Impact
There is significant underestimation of the burden of oste-
oporosis in East Asia. While hip fractures is a useful surrogate
to quantify the socioeconomic burden of osteoporosis, the
incidence of hip fractures in East Asia may not be as well
documented as in some Western industrialised countries where
well-maintained large population databases are available.
Large population databases are available in South Korea
(Korean National Health Insurance Program) and Taiwan
Table 2
Age specific vertebral deformity prevalance among East Asia women using different assessment methods (%).
Place Sampling method Method 40e49 50e59 60e69 70e79 >/ ¼ 80 Ref
China Beijing Rochester 4.9 16.2 19 36.6 [28]
Random sample SOF 3.9 10.5 15 31.2
Hong Kong Convenience SOF 19 44 68 [25]
Sample
Hong Kong Convenience Genant's SQ 10.8 (65e69y) 17.4 29.5 [30]
Sample system
Japan Random McCloskey-Kanis 2.7 13.8 17.5 [29]
Sample Criteria
Korea large scale Rochester 4.4 8.7 20.9 26.3 [26]
Community based
Cohort
Taiwan nation-wide Rochester 1.5(40e44),
2.7(45e49)
4.5(50e54),
4.8(55e59)
6.7(60e64),
13.9(65e69)
20.7(70e74),
24.3(75e79)
29.7 [27]
USA.SOF Rochester 24.7 36.5 [28,31]
SOF 22 33.9 [28,31]
Adapted from Tables 2 and 3 in Ref. [25] and Table 4 of Ref. [30].
SOF, Study of Osteoporosis Fractures (Ref. [31]); SOF method, method used in this study, adopted from DM et al. (Ref. [32]); SQ, semi-quantitative.
Rochester, method published by Eastell and colleagues (Ref. [33]).
McCloskey-Kanis criteria (Ref. [34]).
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These databases have high coverage for >90% of the popu-
lation. In Korea, the coverage is 100%. In Japan, a nationwide
survey has been implemented every 5 years since 1987 to
estimate the hip fractures incidence [12]. Recent data on hip
fracture incidence in China [15] and Hong Kong [7] are from
regional statistics and convenience samples, respectively.
Substantial under-reporting is anticipated in some East Asia
countries. A significant amount of patients in rural areas with
hip fractures may not be known to medical system because of
long distances to the hospital. The facilities for surgical
management are also limited in local health care facilities.
Moreover, these patients may not have the money to pay for
prosthetics. Therefore, many are managed at home or die
without access to the medical system. Means to improve ac-
curacy in documentation will enable a more precise estimation
of the impact and may help facilitate better health-care
planning.
The mortality after hip fracture was generally lower in East
Asia [40e43] compared to the USA [44] and UK [45].
However, the increased mortality was still substantial [46].
The 1-year mortality rate following a hip fracture in Japan,
South Korea and Taiwan were reported to be 11.5% [40],
16.55% [41] and 14% [42], respectively. In Hong Kong, the
age-adjusted 360-day mortality rate was 22.4% and 16.4% for
men and women, respectively, in 2009 [43]. The mortality
after a hip fracture was higher in Korea for males, those in the
lower socioeconomic status, those living in places other than
the capital city, those not taking anti-osteoporosis drugs after
the fracture, and those who received operations from more
specialised hospitals [41], which might reflect more severe
fractures. In Taiwan, a higher mortality rate was noted in more
elderly subjects (HR 7.34 for aged >84 vs. <70 years), in-
dividuals with certain medical conditions (HR 2.4e6.12) and
cases of delayed operations (HR 2.86 for delay >48 h vs.
24 h) [42]. Functional level deteriorated in 60% of hipfracturepatients [47]. An improved model of care may lower
the mortality rate and improve the clinical outcomes [48].
Vertebral fractures also increase mortality [49] and lead to
decline in functional state [50]. Mortality is correlated with the
number of vertebral fractures [49]. Even morphometric
vertebral fractures [47] or osteoporosis in general [51] were
associated with a higher mortality rate in the Japanese
population.
Osteoporosis leads to deterioration in quality of life (QOL)
and quality-adjusted-life-year (QALY) loss. Quantitative anal-
ysis of the QOL among osteoporosis subjects has been carried
out in China [52], Hong Kong [53], Japan [54e56], South
Korea [57] and Taiwan [58]. These studies showed that, among
East Asia populations, osteoporosis was associated with a
decrease in QOL, which improved with treatment. Data on
QALY loss due to fractures was only available for Japan [59].
The cost-effective of drug intervention is usually expressed as
fracture risk reduction or QALY gained. Treatment for osteo-
porosis was considered more cost-effective if offered to sub-
jects at higher risk of fracture. This threshold for treatment also
depends on the willingness to pay of different societies. Similar
to many western countries [60], with a threshold of US dollars
30,000 per QALY gained, intervention for osteoporosis was
considered to be cost-effective in Japan [59].
Data on health-care costs of fractures are sparser for East
Asia societies compared to the West. Even within East Asia,
the socioeconomic situation is diverse, and willingness to pay
for prevention and treatment for osteoporotic fractures varies
within the region. In western China, the annual total cost of
hip fracture was RMB 27,283 per person-year while that for
vertebral fracture was RMB 21,474 in 2010. The annual rate of
increase in cost is 6%, so the cost is expected to be five times
these figures by 2050 [61]. In Hong Kong, the acute hospital
care cost of hip fractures in 1996 amounted to 1% of the total
annual hospital budget, or US $17 million, for a population of
6 million [62]. Medical expenditures related to hip fractures
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for all fractures in Japan was USD $4863 million in 2002.
Reimbursement records in Korea showed that the number of
patients receiving medical treatment related to osteoporosis
increased from 1,034,399 to 1,392,189 for women and from
120,496 to 171,902 for men between 2004 and 2008 [64].
4. Unmet needs4.1. Under-diagnosis and under-treatmentOsteoporosis is greatly under-diagnosed and under-treated
in this region, even among the highest-risk patients who
have already suffered fractures. A recent study [65] was
conducted using patient surveys and medical charts of post-
menopausal women discharged after hip fractures from treat-
ment centres in China, Hong Kong, Singapore, South Korea,
Malaysia, Taiwan, and Thailand. Bone mineral density (BMD)
measurement was only performed in 28.2% of patients prior to
hip fractures; 51.5% were informed that they had osteoporosis
after hip fractures, and 33.0% received medications for oste-
oporosis in the 6 months after discharge. The International
Osteoporosis Foundation (IOF) Asian Pacific Regional Audit
also highlighted that osteoporosis was greatly neglected [1].
The number of dual energy X-ray absorptiometry (DXA)
machines is inadequate across the region and in most cases not
reimbursed. In Hong Kong, history of prior spine or hip
fractures is required for reimbursement of anti-osteoporosis
drugs in public sector. Fracture liaison services are not com-
mon across the region. The barriers to screening, assessment
and treatment of high-risk subjects are discussed below.4.2. Paucity of dataThe exact burden of hip fractures is not well delineated in
some East Asia countries/regions. There is scant data on post-
acute care expenses and productivity loss after hip fracture.
Corresponding data for vertebral and other fractures are even
sparser. The lack of solid epidemiological and economic data
is a major hindrance in convincing health authorities about the
importance of osteoporosis under resources constraints.4.3. Suboptimal awareness/knowledge and financial
constraintsThe awareness of osteoporosis among the public and pro-
fessionals is generally suboptimal. College students in China
knew less about osteoporosis and had a greater barrier to reduce
their risk via lifestyle changes, compared to college students in
USA [66]. In Hong Kong, 91% of doctors considered osteo-
porosis to be under-diagnosed because of its asymptomatic
nature, the inaccessibility to care, and the high cost of di-
agnostics [67]. 33% of doctors were not aware of the guidelines
for BMD testing [67]. Only <30% and 55% of doctors would
perform BMD and prescribe medication, respectively, when
faced with patients with fractures [67]. Another survey in Hong
Kong reviewed that majority of subjects were willing to pay foranti-osteoporotic treatment if the price could be lowered [68].
In Japan, only 61% of doctors in various specialities know about
the diagnostic criteria for osteoporosis [69]. Among Korean
women with osteoporosis, only 37.5% were aware of their
diagnosis and 23.5% received treatment. Easily identifiable risk
factors (e.g., history of fracture, falls, height loss, family his-
tory) were not associated with increased awareness and treat-
ment [70]. In most East Asia countries/regions, government
policies for the prevention and treatment of osteoporosis are
lacking, although non-government organisations are active in
this area. In China, the osteoporosis prevention and awareness
program is restricted to urban areas. DXA machines are only
available in the more economically developed areas of the
country, but still many people cannot afford to pay for the
test. The use of pharmaceutical therapies for osteoporosis
varies markedly between urban and rural areas and from the
north to south of the country.4.4. Lack of cost-effectiveness analysisThere is a general lack of studies on cost-effective
screening and intervention thresholds. Related to this, sup-
port towards reimbursement for screening and treatment is not
optimal. Screening of osteoporosis is supported by policy only
in Japan [12]; screening was considered to be not suitable in
Hong Kong [71]. The criteria for screening and threshold for
treatment need to be developed for individual populations
based on their own epidemiology data and economic situation.
The World Health Organization (WHO) recommended the use
of QALYs gained and willingness-to-pay to determine the
intervention thresholds for osteoporosis on a country-to-
country basis [72]. Both QALYs gain and willingness-to-pay
depend on the gross domestic product (GDP) of individual
countries/regions and vary widely. The GDP per capita (USD,
2012) for China, Hong Kong, Japan, South Korea and Taiwan
is 6076, 36,667, 46,736, 23,113 and 20,328, respectively,
compared to 49,922 for the US [73]. A treatment that gains
one QALY at a cost equivalent to under two times the per
capita GDP is normally considered to be a cost-effective
treatment [74]. The cost-effectiveness of screening followed
by treatment based on local data is available only for Japan
[75]. According to this study, it was cost effective to provide
BMD measurement to women aged 70 years and over who had
a vertebral fracture in the preceding 2 years and treat those
who were osteoporotic, assuming a cost per QALY threshold
of 100,000 US dollars.
5. Risk factors for fractures5.1. Bone mineral densityLow BMD is an important determinant for fractures and
treatment guidelines have traditionally been based on BMD
[76]. The use of population-specific databases can adjust in
part for significant differences in body size between Asians
and Caucasians. The BMD of Asian women differed little
from that of Caucasian women after adjustment for body size
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available for China [78,79], Hong Kong [80], Japan [81],
South Korea [82] and Taiwan [83]. The International Society
for Clinical Densitometry (ISCD) recommended the devel-
opment of a uniform Asian male and female database [84].
However, when compared across populations, the WHO
recommended using the third US National Health and
Nutritional Examination Survey (NHANES III) reference
database as a standardised international hip reference for
women and men of all ethnic groups [84]. In Japan, 80% and
70% young adult mean [85] for subjects with or without
prior fractures, respectively, are used to define osteoporosis
instead of using the T-score. A BMD 25% lower than the
peak BMD has also been used as criteria for diagnosis of
osteoporosis in China [86]. In East Asia, there is currently an
uneven geographic distribution of DXA, which is the gold
standard for measurement of BMD. There are also differ-
ences in the availability of qualified staff to operate the
scanners and inadequate running cost.
Limited access to DXA in East Asia has led to Quantitative
ultrasonometry (QUS) measurements of the calcaneus as an
accepted alternative tool [87e90]. QUS has the potential for
widespread use owing to its portability, low cost, and lack of
ionising radiation. Studies on the ability of QUS to predict
fractures among East Asia populations were only available in
Hong Kong and Japan. QUS can predict non-vertebral frac-
tures in Japanese men and women [91], but its ability to
predict major fractures was inferior to DXA among Chinese
men [90]. The economic evaluation of QUS as a pre-screening
test for the identification of patients with osteoporosis is
available in the West [92], but not in East Asia.
Screening tools based on risk factors have been used to
identify subjects, who are likely to be osteoporotic, for DXA.
The Osteoporosis Self-Assessment Tool for Asians (OSTA),
based on only age and weight, was developed for Asians and
later validated for Caucasians. The OSTA has been evaluated in
China [93,94], Hong Kong [95,96], Japan, Korea and Taiwan
[97]. The OSTA cut-off of 1 had a sensitivity of 59.1e91%
and a specificity of 45e66%, depending on the population, sex
and whether a femoral neck or lumbar spine T-score was used as
a reference. Usage of this simple pre-screening tool allows for a
more sensible use of DXA under limited resources, but no cost-
effectiveness analysis of such an approach has been performed.5.2. Clinical risk factorMany clinical risk factors for fractures have been identified
in various East Asia populations (Table 3). In order to improve
fracture prediction, effort has been invested to find out clinical
risk factors which predict fractures independent of BMD.
Likely candidates include age, prior fracture, concomitant
diseases, history of fall and factors leading to increased pro-
pensity to fall.
The increased fracture risk in subjects with concomitant
disease may due to frailty and increase susceptibility to fall
[104]. However, it may also be related to worsen bone quality.
This observation mainly comes from Japanese literature. Saitoet al. and others have published extensively on bone quality
markers (homocysteine, pentosidine) as well as collagen cross-
links and suggested their relationship with bone strength and
fractures [105,106]. Pentosidine (serum or urine) and homo-
cysteine (serum) levels have been suggested to be useful for
fracture prediction in osteoporotic and diabetic subjects
[105,107]. According to the Japanese guidelines [76], a
vigorous assessment for osteoporosis is recommended in pa-
tients with diabetes and chronic renal disease. Osteoporosis
associated with diabetes and chronic renal failure is mainly
related to deterioration in bone quality, whereas BMD is
relatively well-preserved. Treatment was recommended as
soon as the T-score falls in the osteoporotic range.
History of fall and factors leading to increase propensity to
fall can predict fracture independent of BMD [100]. However
whether this risk is amendable by medication is questionable
according to western literature [108]. Fall prevention pro-
grammes should be offered to this group of subjects with
increased fall risk.
6. Assessment of fracture risk6.1. DXA as screeningCurrently, DXA is offered every 5 years for women between
40 and 70 years old under the Health Promotion Law in Japan,
regardless of clinical risk factor [76]. However, the screening rate
was only 4.6% in 2005 [76]. In Hong Kong [109] and Taiwan
[110], the screening recommendations by professional bodies are
based on the 2010 AsiaePacific Panel Consensus Meeting of the
ISCD [84] and the 2008 National Osteoporosis Foundation
(NOF) guidelines [111]. The screening recommendations in
these two regions are actually similar. BMD testing is indicated
for women aged 65 or men aged 70 and older, postmenopausal
women under age 65 with risk factors for fracture, peri-
menopausal women with clinical risk factors or high-risk medi-
cation use,men aged between 50 and 70with clinical risk factors,
adults with a fragility fracture, adults with a disease or condition
or prescribedmedications associatedwith low bonemass or bone
loss, anyone being considered for pharmacologic therapy or
being treated to monitor treatment effect. However, these
screening strategies were not based on local cost-effective anal-
ysis as in the Western countries [112]. Except in Japan, DXA is
only reimbursed under certain criteria; for example, DXA is only
reimbursed in the event of endocrine disorders or prior fractures
in Taiwan. The cost of DXA is often too high for an averagewage
earner without reimbursement. According to a cost-effective
analysis in Japan, providing DXA to women 70years with
vertebral fracture over the past 2 years and treatment with
risedronate for osteoporotic subjects was cost-effective,
assuming a cost per QALY threshold of US $100000 [75].6.2. Clinical risk factor models for calculation of
absolute fracture riskAlthough BMD is the foundation for diagnosis of osteo-
porosis, use of BMD alone as an intervention threshold is
Table 3
Clinical risk factors for fractures.
Place N Sex Type of study Setting Risk factors Outcome Ref
China 273 M þ F Prospective Hospital based age (>75 y, HR1.23, >85, HR1.68)
female sex HR1.6
prior VF HR1.62
prior HF HR 1.27
BMD T-score < 3.5 HR 1.38
weaken motor skill HR 1.27
Refracture [98]
Beijing,
China
402 PMF Cross-sectional Random
sample
age per 5 years OR 1.5
prior fracture OR 2.2
BMD OR/SD 2.4e2.5
history of heavy physical labour OR 0.1
Morphometric
VF
[23]
Hong
Kong
1810 M Prospective Convenience,
those attend
education fair
history of fall* RR ¼ 14.5
FN T-score </ ¼ 2.5 RR ¼ 13.8
L1-4 T-score </ ¼ 2.5 RR 4
history of fraility fracture RR4.4
outdoor activity <60 min/d RR 4.1
BMI<20 HR3.6
difficulty bending forward RR 3.6
use of walking aid RR 2.7
age  65 RR 2.7
All low-trauma
fracture except
skull, fingers/toes
[99]
Hong
Kong
1435 PMF Prospective Convenience,
those attend
education fair
use of walking aid* RR ¼ 4.2
1 falls in 12 mths RR ¼ 4
Housebound RR ¼ 3.7
Dietary calcium intake <400 mg/d RR ¼ 3.1
age (per 10y) RR ¼ 2.2
fracture history RR ¼ 2.2
BMI <19 kg/m2 RR ¼ 1.8
FN BMD per SD RR ¼ 2
L1-4 BMD per SD RR ¼ 1.5
All low-trauma
fracture
except skull,
fingers/toes
[100]
Hong
Kong
2178 PMF Cross-sectional Convenience,
those attend
education fair
age every 5 years OR 1.6
BMI OR 1.05
menarche age OR 1.2 years since menopause OR 1.08
current smoking or drinking OR 1.99
calcium intake <400 mg/d OR 1.46
fracture history OR 3.8
fall in last 12 months OR 3.27
BMI OR 1.05
T-score at L1-4 or FN OR 1.5
Morphometric
VF
[25]
Japan
(FRISC)
1787 PMF Prospective Hospital based
cohort
age þ 10 years RR 1.62
weight þ 10 kg RR 1.25
prior fracture RR 2
back pain RR 1.58
LS BMD þ 1 T-score 0.85
Major
osteoporotic
fracture
[101]
Korea 1541 F Cross-sectional Voluntary
sample
age
T-score </ ¼ 2.5 RR 2.31 vs > 2.5
parental hip fracture RR 3.29
Fractures at any
site
[102]
1155 M Cross-sectional age
hip circumference OR 1.682
low T-score
prior fracture OR 2.288
low income
low education
for women: menopause, years
since menopause, number of
deliveries/pregnancies
Morphometric
VF
[26]
1529 F
Taiwan 228 M þ F Case controlled low milk intake/peak flow rate/hand grip strength in F
low mini-mental state examination in M
low BMD in both sexes
[103]
497
control
Only studies which include BMD measured by DXA in the analysis are quoted here.
BMI, body mass index; PMF, Postmenopausal female; FN, femoral neck; BMD, bone mineral density; LS, lumbar spine; VF, vermian fossa; DXA, dual-energy
X-ray absorptiometry.
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Table 4
Comparison of 10-year FRAX probabilities for major osteoporotic fractures.
FRAX probability <10% 10e15% >15%
China men 5.4
women 6.9
Hong Kong men 12
women 14
Japan men 13
women 17
South Korea men 11
women 15
Taiwan men 16
women 19
Adapted from Ref. [10].
The clinical scenario is an individual aged 65 years with a prior fragility
fracture (and no other clinical risk factor), a T-score of 2.5 and body mass
index of 24 kg/m2.
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sensitive enough for fracture prediction, as a significant per-
centage of fractures occurred in non-osteoporotic subjects.
There has been a paradigm shift from using BMD alone to
guide treatment to the combine use with clinical risk factors to
calculate the absolute fracture risk for an individual. Due to
the barrier to the usage of DXA as a screening tool in East
Asia, efforts were made to investigate whether it is possible to
use clinical risk factors only to identify high-risk subjects for
treatment, as is the case for the National Osteoporosis
Guideline Group (NOGG) guideline in the UK [113].
Various algorithms for prediction of 5- and 10-year fracture
risk have been developed [114e116]. Among them, FRAX is
probably the one that is used most widely. The FRAX® model
was developed using nine cohort studies, including the Japa-
nese Hiroshima cohort [117]. It is validated by 11 independent
cohort studies, including the Japanese Miyama cohort [118].
FRAX is a major achievement in terms of the measurement of
absolute fracture risk. However, there have been some con-
troversies as to the applicability of FRAX on different ethnic
groups [119]. The development of FRAX was largely based on
data collected from Caucasian populations. The only Asian
population present in the derivation and validation cohorts of
FRAX was from Japan. However, it was also shown that
FRAX underestimated the fracture risk in Japanese pop-
ulations [120]. This was because the gradient of risk/SD for
hip fractures in the Miyama cohort for subjects aged 70 years
was significantly higher than in FRAX [120]. Moreover,
FRAX assumes the relationship between BMI and mortality is
constant across ethnic groups [121]. The ratio of hip fractures
to other fractures is also assumed to be similar to Sweden for
those countries where this ratio is not available [122]; how-
ever, this was shown not to be the case [123]. The hip fracture
rates for Hong Kong and Japanese men and women age 65
years were less than half of that in Sweden. However, the
vertebral fracture rates were higher, giving rise to a higher
vertebral fracture to hip fracture ratio. The incidence of
vertebral fractures in a retrospective cohort in Korea was also
higher than that predicted by FRAX [124]. In this study, they
used probability for major osteoporotic fracture as a surrogate
for vertebral fracture. Using lumbar spine BMD instead of
femoral neck BMD in the FRAX model can potentially
improve the prediction [124]. The clinical risk factors are
weighted in FRAX [119]. However, these risk factors may
have different ‘weights’ in East Asia since the prevalence of
many clinical risk factors in FRAX is lower among Asians
compared to Caucasians [120,125].
Despite these limitations, FRAX is still a useful tool to
guide the decision for treatment and has been widely used in
East Asia populations. Population-specific FRAX algorithm,
calibrated to local data on fracture rate and mortality, is
available for China, Hong Kong, Japan, South Korea and
Taiwan. The difference in 10-year probability of major oste-
oporotic fracture between various EA countries/regions (Table
4) not only reflects the difference in fracture risk but also
differences in heterogeneity in mortality [10]. The FRAX
probability from China may be an under-estimation becausethe data used for this calculation were quite old and mostly
from regional statistics.
Some studies in East Asia showed that models using fewer
clinical risk factors might have predictive abilities similar to
that of the full FRAX model. This finding was also evident in
the Western literature [126]. In the Japanese Population-Based
Osteoporosis Cohort Study (JPOS) [120], the predictability for
major osteoporotic fracture was evaluated with 10-year follow-
up data. The AUC for the model based on age, weight, and
femoral neck BMD was similar to that of the full FRAX model.
In another prospective population-based community cohort
study in Japan, with a follow up time of 4 years and including
2613 men and women at a mean age of 65 in Hiroshima, the
model of FRAX plus vertebral fracture status appeared to
provide greater prognostic information regarding future major
osteoporotic fracture compared to FRAX. The gradient of risk/
SD for the 2 models were 2.73 and 2.54, respectively. However,
a simpler model containing age, BMD, prior fracture, and
vertebral fracture status already captured most of the predictive
information with a gradient of risk/SD of 2.67 [127]. The AUC
of FRAX was similar to that of a simple model using
age þ femoral neck BMD in a Hong Kong cohort [125].
The predictive value of FRAX with and without femoral
neck BMD for major osteoporotic fracture and hip fracture,
based on AUC, seems to be similar in Japan [120] and Hong
Kong Chinese [125] populations. This concurs with the
recommendation of Kanis et al. [128] that FRAX without
BMD is suitable for fracture prediction in countries where
DXA facilities are sparse because the prediction with or
without BMD is comparable. However, there is currently no
direct prospective evidence of treatment efficacy based on
individuals with increased fracture risk who are not known to
have low BMD.
An ethnic specific risk factor model, which had a 10%
higher sensitivity than FRAX at a specificity of 0.8 [125] for
the prediction of major osteoporotic fracture, was developed
for Hong Kong postmenopausal women. These clinical risk
factors increased the fracture risk even in the absence of BMD
data [100]. These clinical risk factors reflect poor muscular
function and coordination (Table 3). Fracture risk calculators,
such as the Garvan calculator [115] and QFracture Scores
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risk. A simple indicator of general muscle strength, handgrip
strength, was found to have a comparable predictive power to
BMD for major osteoporotic fracture among Chinese [129].
7. Treatment7.1. Importance of adequate calcium and vitamin D
intakeA recent review suggested possible optimal dietary strate-
gies for long term skeletal health [130]. These include
adequate animal protein intake coupled with dietary calcium
intake of 1000 mg/day and, maintain normal vitamin D level,
increase fruits and vegetables, increase potassium while
reducing sodium intake, increase intake of foods rich in vita-
mins K1 and K2 as well as including bones in the diet.
Traditionally calcium and vitamin D have been viewed as
very important for bone health. However, there have been
recent data challenging this belief. The systematic review
conducted by Bolland et al. concluded that dietary calcium
intake was not associated with risk of fracture in observational
and intervention studies [131]. On the other hand, calcium
supplements lowered the risk of any fracture by a modest but
statistically significant 11% (n ¼ 58.573; RR 0.89, 95% CI
0.81 to 0.96). In this review, only 5 studies comes from East
Asia. 3 [132e134] out of these 5 studies showed low calcium
or milk intake to be related to fracture. Another intervention
study showed that milk supplement retard bone loss but was
not powered to conclude on fracture outcome although the
treatment group did have fewer fracture [135]. According to a
recent Cochrane systematic review, there is high quality evi-
dence showing that vitamin D (not including analog) plus
calcium (compared with control or placebo) reduce the risk of
any fracture, new non-vertebral fracture and hip fracture [136].
On the whole East Asian populations have lower calcium
intake as compare to Western populations [137]. This is sug-
gested that for the prevention of fractures in elderly people and
simultaneous avoidance of possible serious adverse events
related to a high calcium intake, emphasis should be placed on
people with a low intake of calcium rather than increasing the
intake of those already consuming satisfactory amounts [130].
Vitamin D deficiency and inadequate calcium intake are
prevalent in China [138,139], Hong Kong [140,141], Japan
[142,143], Korea [144,145] and Taiwan [146,147].
The situation is most severe in China. In Shanghai, during
the winter season, the prevalence of vitamin D insufficiency
(<30 ng/mL) was 84% in males and 89% in females while the
corresponding figures for vitamin D deficiency (<20 ng/mL)
was 30% and 46%, respectively [138]. The average calcium
intake in China was less than 400 mg in 2002 [139]. The
average calcium intake per day is 400e600 mg in Hong Kong,
Japan, Korea and Taiwan, according to surveys at different
times and for different age groups [141,143,145,147]. 62.8%
of subjects in Hong Kong having levels <30 ng/ml [140].
However, despite this, a substantial amount of physicians and
patients are still unaware of the importance of calcium andvitamin D in osteoporosis prevention and treatment
[148e150]. Vitamin D deficiency also worsens fragility and
increases the risk of falls [151]. Guidelines have highlighted
the importance of calcium and vitamin D [76,109,110,
152,153], but effort is needed to improve the implementation
of these guidelines [150,154]. In Asia, 50e100% of the pop-
ulation is lactose intolerant [155] and thus may be at risk for
calcium inadequacy. Apart from supplements, fish can be a
good source of calcium [156], and a higher fish intake results
in a higher BMD [157,158]. Fatty sea fish is especially a good
source of vitamin D and n-3 polyunsaturated fatty acid which
are beneficial for bone health. The fish highest in calcium
content are those canned with edible bone such as sardine and
salmon, some other sea fish such as cod, anchovy and pike are
also high in calcium content.
We agree with the guidelines that daily intake of 1000 mg
calcium and 800IU vitamin D is beneficial to bone health.
Higher intake will be necessary for elderly, malabsorptive and
osteoporotic subjects especially those who are institutionalized
may need up to 2000 IU vitamin D per day. However, as
pointed out by Avenell et al. [136], what is more important is
indeed the food not the nutrient. E.g. calcium citrate or car-
bonate may not the best for bone health. Calcium hydroxy-
apatite, in the form of bone, may be better [136].7.2. Indications for treatment (Table 5) and intervention
thresholdTreatment guidelines for osteoporotics are available in
China [152], Hong Kong [109], Japan [76], South Korea [153]
and Taiwan [110]. The treatment guidelines in Hong Kong and
Taiwan were based on the National Osteoporosis Foundation
recommendations. The guidelines in Hong Kong, Japan and
Taiwan incorporate FRAX and recommend treatment for
subjects without other indications for treatment (such as prior
fractures or BMD below a cut-off) if their FRAX value get
above a fixed value regardless of age.7.3. Efficacy of drugsThe efficacy of various anti-osteoporotic drugs to increase
BMD and reduce risk of hip fractures and vertebral fractures
has been evaluated in East Asia populations (Appendix A).
Health economic appraisals for the primary and secondary
prevention of fractures have been performed for most anti-
osteoporotic drugs in the Western world [159,160]. These
studies showed that alendronate [159], etidronate [159], risedr-
onate [159], raloxifene [159], teriparatide [159] and strontium
[160] are cost-effective in treating postmenopausal osteoporosis
under well-defined scenarios but with different gain in QALYs.
The size of the QALY gain for each intervention was strongly
related to the age and pre-existing risk of the patient. However,
such data are only available in Japan and there only for risedr-
onate [75]. In a budget impact and economic effect stimulation
study in South Korea, continuous reimbursement coverage for
patients with osteoporosis was shown to reduce total health
budget expenditure through saving fracture cost [162].
Table 5
Screening and treatment guideline.
Guideline Prior fracture, treat if DXA screening Treat if Ref
Hong Kong (use
NOF guidelines)
Fracture at proximal femur or
vertebrae (use NOF guidelines)
ISCD guideline T-score  2.5 at LS or FN
osteopenia þ FRAX MOF risk  20%
osteopenia þ FRAX Hip risk  3% (use NOF guidelines)
[109]
China Postmenopausal women and men
50 years old with fracture at
proximal femur or vertebrae
T-score  2.5 at LS or FN
osteopenia þ OSTA# high risk þ FRAX MOF risk  20%
osteopenia þ OSTA# high risk þ FRAX Hip risk  3%
[61]
Japan Fracture at proximal femur or
vertebrae
other sites þ BMD <80% YAM*
for 40e70 years old female
if <80%: further exam 80%
but <90%: advice
90% þ RF:advice
BMD <70% YAM
70% but <80% þ FH proximal femoral fracture
70% but <80% þ FRAX (MOF)  15%
[76]
Korea Radiographic evidence of an
osteoporotic fracture.
minimum T-score of  3.0 at LS or femur [153]
Taiwan Osteoporotic fracture after age 50 65 both sexes
<65 with CRF both sexes
FRAX MOF risk 20%
FRAX HF risk 3%
[110]
LS, lumbar spine; FN, femur neck; MOF, major osteoporotic fracture; HF, hip fracture; YAM, young adult mean; FH, family history; RF, risk factors; CRF, clinical
risk factors; OSTA, osteoporosis self assessment tool for Asians.
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oporosis or prior hip or vertebral fracture, the National Osteo-
porosis Foundation guideline recommended treatment if FRAX
value  20% for major osteoporotic fracture or 3% for hip
fracture. However, the National Osteoporosis Foundation
guidelines are based on cost-effectiveness that produces a 35%
prevention rate for 5 years according to the epidemiology and
mortality data in the USA [111]. Direct application of the Na-
tional Osteoporosis Foundation guidelines in other countries is
not optimal. Fujiwara et al. [161] reported that FRAX would
underestimate the risk of major osteoporotic fracture in the
Japanese population. A FRAX cut-off value of 15% for major
osteoporotic fracture (MOF) was recommended as the treat-
ment threshold in subjects with low bone mass in Japan [163]
instead of 20% used by National Osteoporosis Foundation.7.4. Osteoporosis in menThere is much less research in men than in women in Asia.
Thus, further studies are necessary to find a cost-effective
screening method and intervention threshold in men [164].7.5. Difference in prescription habitsThere are several anti-osteoporotic drugs that are only
available in Japan and not in other countries. These include
Eldecalcitol (vitamin D3 analog), Menatetrenone (Vitamin K
derivatives) and Minodronic acid (bisphosphonate developed
in Japan) [165]. Aledronate and Risedronate are used at half-
dose in Japan because of the assumption that Asians have a
small body size and smaller skeleton. Bazedoxifene is only
used in Japan and South Korea, but not in other EA countries.
Herbal medicine is often used in China and Hong Kong for
treatment of osteoporosis. A recent Cochrane review, which
involved 10,655 participants, showed that Chinese herb Migu
decoction (when compared with placebo) was associated with
an increase in lumbar BMD of 0.16 g/cm3 (CI 0.06e0.26).
Qianggu soft extract (vs no intervention) produced an increase
in femoral neck BMD of 0.09 g/cm3 (CI 0.03e0.13).Xianlinggubao plus caltrate (vs caltrate) produced increase in
femoral neck BMD of 0.3 g cm3 (CI 0.25e0.35) [166]. No
fracture data was available. All the studies included were
small in sample size and tested different herbal medicine.
More studies are required in this area.
Vitamin D analogs are widely used in Japan. For patients
aged 65 years with existing fractures, 22% of doctors chose
activated vitamin D as the first-line treatment compared to
55% who selected bisphosphonates [12]. Among vitamin D
analogs, eldecalcitol was shown to be superior to alfacalcidol
in increasing the BMD and reducing vertebral fractures and
wrist fractures among the Japanese population [167]. A review
from the West showed that adding calcitriol to other anti-
osteoporosis drugs has additional bone-preserving effects
[168]. However, in a recent Japanese study, alendronate plus
alfacalcidol was no more effective than alendronate alone for
overall vertebral fracture prevention, while subgroup analysis
showed that alendronate plus alfacalcidol was more effective
for fracture prevention in high-risk patients and for non-
vertebral weight-bearing bone fracture prevention [169].7.6. Vitamin K derivativesThe importance of vitamin K for bone health was high-
lighted in the Japanese guidelines [76].
Studies showed the possible association between intakes of
vitamin K, such as in fermented soybeans, which is commonly
consumed among Japanese and Koreans, and the risk of hip
fracture [170,171] and vertebral fracture [172]. Intervention
trials also showed that Vitamin K could increase the BMD in
Korean postmenopausal women [173] and prevent fractures in
Japanese individuals [174]. A recent review has addressed the
importance of vitamin K especially K2 on bone health [130].
A large meta-analysis [175] concluded that high vitamin K2
levels were associated with 60% reduction in vertebral fracture
risk, 77% reduction in hip fracture risk and 81% reduction in
non-vertebral fracture risk. The beneficial effect of vitamin K
may not be due to increase in bone mineral density but
improved bone strength [176]. The natto (soybean fermented
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genki”, was granted a health claim [177,178] in Japan.7.7. Non-adherenceAdherence to anti-osteoporotic regimens is also seen as a
problem in East Asia. Data are available from the West con-
cerning the clinical and economic impact of non-adherence
[179,180], but only the former was available in the East Asia
literature [181,182]. In a study conducted based on a claims
database in Taiwan, the overall adherence to anti-osteoporotic
regimens was judged to be sub-optimal. Only 50.8% of pa-
tients continued to receive therapy at 1 year and 36.1% at 2 years
[181]. Even among patients already with vertebral or hip frac-
ture, only 38% of subjects in Taiwan remained compliant on
alendronate during the first year of treatment. Over the 4-year
follow-up period, the risk of hip fracture among the compliant
patients was 70% lower than the noncompliant ones [182].
8. Conclusion
Thegreatest burden of hip fractures in theworld is expected to
rest in East Asia, especially China. However, osteoporosis is
greatly under diagnosed and under treated in East Asia, even for
patients who already had fractures. Efforts should be directed to
improve the assessment and management of at-risk individuals
via the following directions. Firstly, we should aim at better
documentation of the epidemiology of all kinds of osteoporotic
fractures and the related social and economic burden. Secondly,
awareness of and knowledge on osteoporosis among both the
professionals and public should be improved. Such an increased
awareness among public may potentially improve the drug
adherence. Thirdly, clinical risk factor models may be ethnicity-
specific and differ between Asians and Caucasians. More
research is needed to determine the optimal fracture risk
assessment model for East Asia populations. Before this is
available, we may use FRAX as an alternative. Fourthly, cost-
effective screening methods and treatment strategies based on
epidemiological and economic data for specific regions should be
developed. Finally, more research on bone quality and treatment
modalities specific to Asian populations needs to be performed.
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Alendronate: China
- Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, et al. The
efficacy and tolerability of once-weekly alendronate 70
mg on bone mineral density and bone turnover markers in
postmenopausal Chinese women with osteoporosis. J Bone
Miner Metab 2009;27:471-8.Alendronate: HK
- Lau EM, Woo J, Chan YH, Griffith J. Alendronate pre-
vents bone loss in Chinese women with osteoporosis. Bone
2000;27:677-80
- Kung AW, Yeung SS, Chu LW. The efficacy and tolera-
bility of alendronate in postmenopausal osteoporotic
Chinese women: a randomized placebo-controlled study.
Calcif Tissue Int 2000;67:286-90.
- Ho AY, Kung AW. Efficacy and tolerability of alendronate
once weekly in Asian postmenopausal osteoporotic
women. Ann Pharmacother 2005;39:1428-33.
Alendronate: Japan
- Kawate H, Ohnaka K, Adachi M, Kono S, Ikematsu H,
Matsuo H, et al. Alendronate improves QOL of post-
menopausal women with osteoporosis. Clin Interv Aging
2010;26:123-31.
- Iwamoto J, Takeda T, Sato Y, Uzawa M. Determinants of
one-year response of lumbar bone mineral density to
alendronate treatment in elderly Japanese women with
osteoporosis.Yonsei Med J 2004;45:676-82.
- Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga
M, Nakamura T, et al. A double-masked multicenter
comparative study between alendronate and alfacalcidol in
Japanese patients with osteoporosis. The Alendronate
Phase III Osteoporosis Treatment Research Group.
Osteoporos Int 1999;10:183-92
- Iwamoto J, Takeda T, Sato Y, Uzawa M. Early changes in
urinary cross-linked N-terminal telopeptides of type I
collagen level correlate with 1-year response of lumbar
bone mineral density to alendronate in postmenopausal
Japanese women with osteoporosis. J Bone Miner Metab
2005;23:238-42.
- Takeda S, Kaneoka H, Saito T. Effect of alendronate on
glucocorticoid-induced osteoporosis in Japanese women
with systemic autoimmune diseases: versus alfacalcidol.
Mod Rheumatol 2008;18:271-6
- Orimo H, Nakamura T, Fukunaga M, Kakikawa T,
Okuyama K, Okaniwa M, et al; A-TOP (Adequate
Treatment of Osteoporosis) research group. Effects of
alendronate plus alfacalcidol in osteoporosis patients with
a high risk of fracture: the Japanese Osteoporosis Inter-
vention Trial (JOINT) - 02. Curr Med Res Opin
2011;27:1273-84
- Uchida S, Taniguchi T, Shimizu T et al. Therapeutic effects
of alendronate 35 mg once weekly and 5 mg once daily in
Japanese patients with osteoporosis: a double-blind, ran-
domized study. J Bone Miner Metab 2005;23(5):382-8
- Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.
Three-year experience with alendronate treatment in
postmenopausal osteoporotic Japanese women with or
without renal dysfunction: a retrospective study. Drugs
Aging 2012;29:133-42.
- Takada J, Katahira G, Iba K, Yoshizaki T, Yamashita T.
Hip structure analysis of bisphosphonate-treated Japanese
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Metab 2011;29:458-65
Alendronate: Korea
- Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, et
al. Early changes in biochemical markers of bone turnover
predict bone mineral density response to antiresorptive
therapy in Korean postmenopausal women with osteopo-
rosis. Endocr J 2005;52:667-74
- Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, et al.
Effects of a combined alendronate and calcitriol agent
(Maxmarvil) on bonemetabolism inKorean postmenopausal
women: a multicenter, double-blind, randomized, placebo-
controlled study. Osteoporos Int 2006;17:1801-7
Alendronate: Taiwan
- Yen ML, Yen BL, Jang MH, Hsu SH, Cheng WC, Tsai KS.
Effects of alendronate on osteopenic postmenopausal
Chinese women. Bone 2000;27:681-5.
- Lin TC, Yang CY, Yang YH, Lin SJ. Alendronate adher-
ence and its impact on hip-fracture risk in patients with
established osteoporosis in Taiwan. Clin Pharmacol Ther
2011;90:109-16.
Risedronate: Japan
- Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A,
Ninomiya K, et al. Effects of risedronate or alfacalcidol on
bone mineral density, bone turnover, back pain, and frac-
tures in Japanese men with primary osteoporosis: results
of a two-year strict observational study. J Bone Miner
Metab 2009;27:168-74.
- Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M,
Fukao A, et al. Clinical significance of risedronate for
osteoporosis in the initial treatment of male patients with
Graves' disease. J Bone Miner Metab 2006;24:105-13
- Ogura Y, Gonsho A, Cyong JC, Orimo H. Clinical trial of
risedronate in Japanese volunteers: single and multiple
oral dose studies. J Bone Miner Metab 2004;22:111-9
- Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi
A, Inoue T, et al. A comparison of incidences of vertebral
fracture in Japanese patients with involutional osteoporosis
treated with risedronate and etidronate: a randomized,
double-masked trial. J Bone Miner Meta 2004;22:469-78.
Risedronate: Korea
- ChungHY,ChinSO,KangMI,Koh JM,MoonSH,YoonBK,
et al. Efficacy of risedronate with cholecalciferol on 25-
hydroxyvitaminD level and bone turnover inKorean patients
with osteoporosis. Clin Endocrinol (Oxf) 2011;74:699-704.
- ChungYS, Lim SK, ChungHYet al. Comparison ofmonthly
ibandronate versus weekly risedronate in preference, conve-
nience, andbone turnovermarkers inKoreanpostmenopausal
osteoporotic women. Calcif Tissue Int 2009;85:389-97.Ibandronate: China
- Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, et al.
Infusion of ibandronate once every 3 months effectively de-
creases bone resorption markers and increases bone mineral
density inChinese postmenopausal osteoporoticwomen: a 1-
year study. J Bone Miner Metab 2010;28:299-305.
Ibandronate: Japan
Hashimoto J. Therapeutic agents for disorders of bone and
calcium metabolism: Ibandronate [Article in Japanese] Clin
Calcium 2007;17:11-7.
Ibandronate: Korea
- Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS,
et al. Comparison of monthly ibandronate versus weekly
risedronate in preference, convenience, and bone turnover
markers in Korean postmenopausal osteoporotic women.
Calcif Tissue Int 2009;85:389-97.
Zoledronic acid: China
- Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai
KS, et al. The effects of intravenous zoledronic acid in
Chinese women with postmenopausal osteoporosis. J Bone
Miner Metab 2011;29:328-33.
Zoledronic acid: Korea
- Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, et al.
Zoledronic acid prevents bone loss in premenopausalwomen
with early breast cancer undergoing adjuvant chemotherapy:
a phase III trial of the Korean Cancer Study Group (KCSG-
BR06-01). Breast Cancer Res Treat 2011;125:99-106.
Raloxifene: China
- Nakamura T, Liu JL, Morii H, Huang QR, Zhu HM, Qu Y,
et al. Effect of raloxifene on clinical fractures in Asian
women with postmenopausal osteoporosis. J Bone Miner
Metab 2006;24:414-8.
Raloxifene: HK
Kung AW, Chao HT, Huang KE, Need AG, Taechakrai-
chana N, Loh FH, et al. Efficacy and safety of raloxifene 60
milligrams/day in postmenopausal Asian women. J Clin
Endocrinol Metab 2003;88:3130-6.
Raloxifene: Japan
- Nakamura T, Liu JL, Morii H, Huang QR, Zhu HM, Qu Y,
et al. Effect of raloxifene on clinical fractures in Asian
women with postmenopausal osteoporosis. J Bone Miner
Metab 2006;24:414-8.
129E.Y.N. Cheung et al. / Osteoporosis and Sarcopenia 2 (2016) 118e133- Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A,
Ninomiya K, et al. Association between baseline values of
bone turnover markers and bone mineral density and their
response to raloxifene treatment in Japanese postmenopausal
women with osteoporosis. Endocr J 2008;55:41-8
- Majima T, Komatsu Y, Shimatsu A, Satoh N, Fukao A,
Ninomiya K, et al. Clinical significance of 1-year treat-
ment with raloxifene on bone and lipid metabolism in
Japanese postmenopausal women with osteoporosis.
Endocr J 2007;54:855-62.
- Hayashi T, Ina K, Maeda M, Nomura H. The effects of
selective estrogen receptor modulator treatment following
hormone replacement therapy on elderly postmenopausal
women with osteoporosis. Nitric Oxide 2011;24:199-203.
Bazedoxifene: Japan
- Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H,
et al. Effects of bazedoxifene on bone mineral density,
bone turnover, and safety in postmenopausal Japanese
women with osteoporosis. J Bone Miner Res.
2011;26:519-29.
Teriparatide: China
- Zhang XZ, Song LG, Wang B, Yang J, Li H, Xuan M, et
al. A randomized, multicenter, active-controlled trial to
compare the efficacy of recombinant human parathyroid
hormone (1-34) with that of elcatonin in postmenopausal
women with osteoporosis in China. Zhonghua Nei Ke Za
Zhi 2010;49:662-6. Chinese
Teriparatide: HK
- Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam
KS, et al. A comparison of teriparatide and calcitonin therapy
in postmenopausal Asian women with osteoporosis: a
6-month study. Curr Med Res Opin. 2006;22:929-37.
Teriparatide: Japan
- Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M,
Fukunaga M, et al. Randomized Teriparatide [human
parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy
Research (TOWER) trial for examining the reduction in
new vertebral fractures in subjects with primary osteopo-
rosis and high fracture risk. J Clin Endocrinol Metab 2012;
97:3097-106
- Nakamura T, Tsujimoto M, Hamaya E, Sowa H, Chen P.
Consistency of fracture risk reduction in Japanese and
Caucasian osteoporosis patients treated with teriparatide: a
meta-analysis. J Bone Miner Metab 2012;30:321-5.
- Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M,
Thiebaud D, Nakamura T. Effect of teriparatide on bone
mineral density and biochemical markers in Japanese
women with postmenopausal osteoporosis: a 6-month
dose-response study. J Bone Miner Metab 2008;26:624-34Teriparatide: Taiwan
- Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS.
Teriparatide vs. calcitonin in the treatment of Asian
postmenopausal women with established osteoporosis.
Osteoporos Int. 2006;17:373-8.
Strontium: Taiwan
- Hwang JS, Chen JF, Yang TS, Wu DJ, Tsai KS, Ho C, et
al. The effects of strontium ranelate in Asian women with
postmenopausal osteoporosis. Calcif Tissue Int 2008;
83:308-14.
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